|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Anticoagulant Therapy, Administration & Monitoring | | | | NO. | |
| PURPOSE:  To provide specific guidelines for the safe administration of anticoagulants and management of residents receiving anticoagulant therapy.  STATEMENT OF POLICY:  It is the policy of this facility to provide safe administration of physician ordered anticoagulant therapy. This includes resident/family education, staff education, and monitoring of therapeutic levels, side effects and dedication interactions.  PROCEDURE:   1. Procedure to provide Resident/Family education. 2. On admission, Licensed Nurse will provide education to Resident/Family regarding: 3. Type and purpose of anticoagulant therapy ordered. 4. Importance of compliance with anticoagulant medication management. 5. Side effects that should be reported to the Licensed Nurse. 6. Medications/food that might interact with anticoagulant therapy. 7. Blood tests that will be performed to monitor anticoagulant therapy. 8. Physician notification of blood levels, side effects and medication interaction. 9. Documentation of Resident/family education will be recorded in the Nurses Notes section of the medical record. 10. PROCEDURE TO PROVIDE STAFF EDUCATION. 11. Licensed Nursing staff will receive education on Anticoagulant Therapy to include: 12. Purpose of anticoagulant therapy. (to prevent pathological blood clotting) 13. Medical diagnoses for which anticoagulants are prescribed. 14. Types of anticoagulant therapy. 15. Coumadin (Warfarin) 16. Heparin 17. Lovenox (Enoxaparin) 18. Normiflo (Ardeparin) 19. Other 20. Side effects of anticoagulant therapy. 21. Bleeding 22. Bruising 23. Hematoma 24. Hives 25. Skin necrosis 26. Other | | | | | |
| Approved: | Effective Date: | Revision Date: | Change No.: | | Page:  1 of 2 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Anticoagulant Therapy, Administration & Monitoring | | | | NO. | |
| 1. Medication/food interactions. 2. Anti-inflammatory Medications 3. Sulfas (Septra, Bactrim, Gantanol, and Gantrisin) 4. Quinolones (Cipro, Noroxin, Floxin, and Levaquin) 5. Erythromycins (E-mycin, Biaxin, Zithromax, and Dynabac) 6. Vitamin K (Limit intake of leafy greens, cabbage, liver, pork, fish, high fat) 7. Other 8. Lab testing to monitor therapeutic levels, recommended frequency of testing, and normal lab values. 9. PT 10. INR 11. PTT 12. Notification of Physician: 13. Results of lab testing 14. Side effects 15. Medication interactions (notify physician if increase or decrease in INR is noted after the addition of any new medication to the drug regimen.) 16. When to hold anticoagulant medication. (as directed by physician and/or pharmacy policy? 17. Documentation and Monitoring 18. Educational in-service on Anticoagulant Therapy will be provided during Orientation and annually by the Director of Nursing/Staff Development Coordinator/designee. 19. PROCEDURE FOR IDENTIFICATION AND MONITORING OF RESIDENTS ON ANITCOAGULANT THERAPY. 20. Residents receiving anticoagulant drug therapy will be identified by: 21. Insertion of a Nursing Alert sheet that is placed in front of resident’s Medication Administration Record to inform the Licensed Nurses of potentials for interactions with Anti-inflammatory Medications, Sulfas, Quinolones, and Erythromycins. 22. Identifying brightly colored dot will be placed on resident’s medical record, alerting staff that the resident is currently taking anticoagulants. 23. Anti-Coagulation Monitoring Form will be placed in resident’s medical record noting date of lab test, result of test, present dose of anticoagulant, new dose if ordered, repeat lab date and nurses initials. 24. Resident Care Plan will reflect problem, goals, and interventions related to Anticoagulant Medication Therapy.   ATTACHMENTS:  Nursing Alert: For Residents Receiving Coumadin Therapy  Anti-Coagulation Monitoring Form | | | | | |
| Approved: | Effective Date: | Revision Date: | Change No.: | | Page:  2 of 2 |